Personalis (NASDAQ:PSNL) Given New $8.00 Price Target at HC Wainwright

Personalis (NASDAQ:PSNL) had its price target cut by HC Wainwright from $11.00 to $8.00 in a research report sent to investors on Monday,Benzinga reports. They currently have a buy rating on the stock.

Several other research firms have also recently issued reports on PSNL. Needham & Company LLC reissued a “buy” rating and issued a $7.25 target price on shares of Personalis in a research note on Wednesday, January 8th. Lake Street Capital lifted their price objective on Personalis from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th.

Personalis Price Performance

Shares of Personalis stock opened at $5.81 on Monday. Personalis has a one year low of $1.12 and a one year high of $7.20. The business’s 50 day simple moving average is $4.87 and its two-hundred day simple moving average is $4.72. The stock has a market capitalization of $410.48 million, a P/E ratio of -3.46 and a beta of 1.75.

Personalis (NASDAQ:PSNL) last issued its earnings results on Wednesday, November 6th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.31). The firm had revenue of $25.71 million during the quarter, compared to analysts’ expectations of $20.67 million. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. During the same period in the previous year, the firm earned ($0.51) earnings per share. Sell-side analysts expect that Personalis will post -1.37 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Personalis

Several hedge funds and other institutional investors have recently modified their holdings of PSNL. nVerses Capital LLC bought a new stake in Personalis during the 3rd quarter valued at approximately $40,000. SG Americas Securities LLC purchased a new position in shares of Personalis in the 4th quarter valued at approximately $63,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Personalis during the fourth quarter valued at approximately $87,000. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its holdings in Personalis by 42.5% in the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company’s stock worth $81,000 after purchasing an additional 4,504 shares in the last quarter. Finally, International Assets Investment Management LLC raised its holdings in Personalis by 438.0% in the third quarter. International Assets Investment Management LLC now owns 20,982 shares of the company’s stock worth $113,000 after purchasing an additional 17,082 shares in the last quarter. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.